CASI Pharmaceuticals, Inc (DE) Quarterly Debt-to-equity in % from Q2 2015 to Q4 2022

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
CASI Pharmaceuticals, Inc (DE) quarterly Debt-to-equity history and growth rate from Q2 2015 to Q4 2022.
  • CASI Pharmaceuticals, Inc (DE) Debt-to-equity for the quarter ending December 31, 2022 was 54 %, a 79.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2022 54 +24 +79.7% Dec 31, 2022
Q3 2022 46.9 +18.3 +63.9% Sep 30, 2022
Q2 2022 37.4 +10.7 +39.8% Jun 30, 2022
Q1 2022 33.7 +10.4 +44.3% Mar 31, 2022
Q4 2021 30.1 +10.2 +51.2% Dec 31, 2021
Q3 2021 28.6 +13.3 +86.3% Sep 30, 2021
Q2 2021 26.8 +15.4 +136% Jun 30, 2021
Q1 2021 23.4 +12.7 +120% Mar 31, 2021
Q4 2020 19.9 +10.7 +116% Dec 31, 2020
Q3 2020 15.4 +8.35 +119% Sep 30, 2020
Q2 2020 11.4 +5.21 +84.7% Jun 30, 2020
Q1 2020 10.6 +5.28 +98.7% Mar 31, 2020
Q4 2019 9.19 +4.2 +84.1% Dec 31, 2019
Q3 2019 7.01 -0.01 -0.14% Sep 30, 2019
Q2 2019 6.15 -4.29 -41.1% Jun 30, 2019
Q1 2019 5.35 -12.2 -69.5% Mar 31, 2019
Q4 2018 4.99 -25.7 -83.7% Dec 31, 2018
Q3 2018 7.02 -31.7 -81.9% Sep 30, 2018
Q2 2018 10.4 -30.2 -74.3% Jun 30, 2018
Q1 2018 17.6 -30.2 -63.2% Mar 31, 2018
Q4 2017 30.7 -36.3 -54.2% Dec 31, 2017
Q3 2017 38.7 -122 -75.9% Sep 30, 2017
Q2 2017 40.7 -1.07K -96.3% Jun 30, 2017
Q1 2017 47.8 +522 Mar 31, 2017
Q4 2016 67 +364 Dec 31, 2016
Q3 2016 161 +617 Sep 30, 2016
Q2 2016 1.11K +2.08K Jun 30, 2016
Q1 2016 -474 Mar 31, 2016
Q4 2015 -297 Dec 31, 2015
Q3 2015 -456 Sep 30, 2015
Q2 2015 -974 Jun 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.